Global Ovarian Cancer Drugs Market Outlook, 2019-2023 with AstraZeneca, Clovis Oncology, F. Hoffmann-La Roche, Spectrum Pharmaceuticals, and Tesaro Dominating - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Feb 13, 2019--The “Global Ovarian Cancer Drugs Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering.
The ovarian cancer drugs market will register a CAGR of over 22% by 2023.
Ovarian cancer is the second most common gynecologic cancer, and the incidence of the disease has been increasing. The incidence of ovarian cancer increases with age, mainly due to the cell DNA damage associated with age as a result of biological processes or due to the exposure to risk factors.
In terms of the incidence rate, ovarian cancer is the eighth-most commonly occurring malignancy in women and the eighteenth-most common cancer overall. Thus, the increase in the incidence of ovarian cancer is expected to drive the growth of the global ovarian cancer drugs market during the forecast period.
Increasing awareness of ovarian cancer
The increasing awareness of ovarian cancer among physicians and patients is expected to drive the growth of the market during the forecast period. This has led to increased awareness among healthcare workers regarding the symptoms of ovarian cancer and the options to manage the disease.
High cost of treatment
The treatment of ovarian cancer is costly and imposes a high economic burden on the national healthcare system and on individuals. Hence, even though cost-effective oral chemotherapy drugs are available for the treatment of ovarian cancer often they are not offered to Medicare patients due to the above regulation and patients need to spend significant out-of-pocket costs. Hence, the cost of the treatment is a significant challenge in the market.
The market appears to be moderately fragmented and with the presence of several companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Key PlayersAstraZeneca Clovis Oncology F. Hoffmann-La Roche Spectrum Pharmaceuticals Tesaro
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPEMarket ecosystem Market characteristics Market segmentation analysis
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZINGMarket definition Market sizing 2018 Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSISBargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry
PART 07: MARKET SEGMENTATION BY TYPEComparison by type Epithelial ovarian cancer - Market size and forecast 2018-2023 Germ cell ovarian cancer - Market size and forecast 2018-2023 Stromal cell ovarian cancer - Market size and forecast 2018-2023 Small cell ovarian cancer - Market size and forecast 2018-2023 Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPEGeographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 RoW - Market size and forecast 2018-2023 Key leading countries Market opportunity
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPEOverview Landscape disruption
PART 13: VENDOR ANALYSISVendors covered Vendor classification Market positioning of vendors AstraZeneca Clovis Oncology F. Hoffmann-La Roche Spectrum Pharmaceuticals Tesaro
For more information about this report visit https://www.researchandmarkets.com/research/p2k932/global_ovarian?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190213005495/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Ovarian Cancer Drugs
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 02/13/2019 10:09 AM/DISC: 02/13/2019 10:09 AM